Our goal is to revolutionize drug development in order to create better therapies for patients. Medicines today are often toxic and unselective, working only for a small percentage of patients and leaving behind a trail of negative side effects. We aspire to change this paradigm and are developing highly selective, targeted medicines, that address known mutations in patients that have been pre-selected to respond effectively to our therapy.
We leverage our in-house drug design and operational expertise to create novel small molecules against genetically defined forms of cancer. We then move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful medicines for patients in need.